Schanz, Julie

[["dc.bibliographiccitation.firstpage","254"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Journal Of Haematology"],["dc.bibliographiccitation.lastpage","256"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Steuernagel, Peter"],["dc.contributor.author","Shirneshan, Katayoo"],["dc.contributor.author","Baesecke, Joerg"],["dc.date.accessioned","2018-11-07T09:52:53Z"],["dc.date.available","2018-11-07T09:52:53Z"],["dc.date.issued","2015"],["dc.description.abstract","A 62-yr-old man with two healthy daughters was diagnosed with osteomyelofibrosis. To our surprise, a female XX-karyotype was observed in bone marrow and confirmed in PHA-stimulated T-lymphocytes from peripheral blood. Further molecular genetic investigation revealed a submicroscopic translocation between the short arm of X and Y, which leads to an XX-male genotype based on an unbalanced translocation X;Y. This rare coincidence was further accentuated as the USP9Y gene, suspected to be to be involved in sperm cell production, was absent, but no azoospermia was present. In general, routine cytogenetics may result in findings that need to be further delineated and, as here, lead to a rare observation."],["dc.identifier.doi","10.1111/ejh.12555"],["dc.identifier.isi","000359600500009"],["dc.identifier.pmid","25808090"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36217"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1600-0609"],["dc.relation.issn","0902-4441"],["dc.title","Primary osteomyelofibrosis and an XX-male genotype"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","820"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","829"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Luno, Elisa"],["dc.contributor.author","Cervera, Jose"],["dc.contributor.author","Granada, Isabel"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Steidl, Christian"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, Thomas"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Faderl, Stefan"],["dc.contributor.author","Pierce, Sherry"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:12:21Z"],["dc.date.available","2018-11-07T09:12:21Z"],["dc.date.issued","2012"],["dc.description.abstract","Purpose The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the International Prognostic Scoring System (IPSS) in 1997, knowledge concerning the prognostic impact of abnormalities has increased substantially. The present study proposes a new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients. Patients and Methods Patients were included from the German-Austrian MDS Study Group (n = 1,193), the International MDS Risk Analysis Workshop (n = 816), the Spanish Hematological Cytogenetics Working Group (n = 849), and the International Working Group on MDS Cytogenetics (n = 44) databases. Patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only were evaluated for overall survival (OS) and AML evolution. Internal validation by bootstrap analysis and external validation in an independent patient cohort were performed to confirm the results. Results In total, 19 cytogenetic categories were defined, providing clear prognostic classification in 91% of all patients. The abnormalities were classified into five prognostic subgroups (P < .001): very good (median OS, 61 months; hazard ratio [HR], 0.5; n = 81); good (49 months; HR, 1.0 [reference category]; n = 1,809); intermediate (26 months; HR, 1.6; n = 529); poor (16 months; HR, 2.6; n = 148); and very poor (6 months; HR, 4.2; n = 187). The internal and external validations confirmed the results of the score. Conclusion In conclusion, these data should contribute to the ongoing efforts to update the IPSS by refining the cytogenetic risk categories. J Clin Oncol 30: 820-829. (C) 2012 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2011.35.6394"],["dc.identifier.isi","000302626600017"],["dc.identifier.pmid","22331955"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26930"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","0732-183X"],["dc.title","New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Deitken, Sven"],["dc.contributor.author","Seraphin, Joerg"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Bruemmendorf, Tim Henrik"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Boehme, Angelika"],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T08:36:46Z"],["dc.date.available","2018-11-07T08:36:46Z"],["dc.date.issued","2010"],["dc.format.extent","1211"],["dc.identifier.isi","000289662203269"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18387"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","52nd Annual Meeting of the American-Society-of-Hematology (ASH)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","900"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","906"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Götze, Katharina S."],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Blau, Igor W."],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","Seraphin, Jörg"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Böhme, Angelika"],["dc.contributor.author","Schmidt, Burkhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:22:10Z"],["dc.date.available","2018-11-07T09:22:10Z"],["dc.date.issued","2013"],["dc.description.abstract","The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Celgene(R) Germany"],["dc.identifier.doi","10.1016/j.leukres.2013.03.019"],["dc.identifier.isi","000321111900012"],["dc.identifier.pmid","23623559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0145-2126"],["dc.title","Molecular cytogenetic monitoring from CD34+peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","902"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","910"],["dc.bibliographiccitation.volume","128"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sanz, Guillermo F."],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Bowen, David"],["dc.contributor.author","Fenaux, Pierre"],["dc.contributor.author","Dreyfus, Francois"],["dc.contributor.author","Kantarjian, Hagop M."],["dc.contributor.author","Kuendgen, Andrea"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Cazzola, Mario"],["dc.contributor.author","Cermak, Jaroslav"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Levis, Alessandro"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Maciejewski, Jaroslaw P."],["dc.contributor.author","Machherndl-Spandl, Sigrid"],["dc.contributor.author","Magalhaes, Silvia M. M."],["dc.contributor.author","Miyazaki, Yasushi"],["dc.contributor.author","Sekeres, Mikkael A."],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Tauro, Sudhir"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Vallespi, Teresa"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Greenberg, Peter L."],["dc.date.accessioned","2018-11-07T10:10:07Z"],["dc.date.available","2018-11-07T10:10:07Z"],["dc.date.issued","2016"],["dc.description.abstract","In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower-and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making."],["dc.description.sponsorship","MDS Foundation, Inc."],["dc.identifier.doi","10.1182/blood-2016-02-700054"],["dc.identifier.isi","000383834800008"],["dc.identifier.pmid","27335276"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39793"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Time-dependent changes in mortality and transformation risk in MDS"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Nephrology"],["dc.contributor.author","Hakroush, Samy"],["dc.contributor.author","Lehnig, Luca-Yves"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2021-08-12T07:46:15Z"],["dc.date.available","2021-08-12T07:46:15Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s40620-021-01109-8"],["dc.identifier.pii","1109"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88657"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.relation.eissn","1724-6059"],["dc.relation.issn","1121-8428"],["dc.title","Renal involvement of intravascular large B-cell lymphoma: a challenging diagnosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2476"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2480"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Hellige, Niels"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Binder, Mascha"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:43:56Z"],["dc.date.available","2020-12-10T18:43:56Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.3109/10428194.2016.1151510"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78273"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","73483"],["dc.bibliographiccitation.issue","43"],["dc.bibliographiccitation.journal","Oncotarget"],["dc.bibliographiccitation.lastpage","73500"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Orazi, Attilio"],["dc.contributor.author","Steensma, David P."],["dc.contributor.author","Ebert, Benjamin L."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Westers, Theresia M."],["dc.contributor.author","Wells, Denise A."],["dc.contributor.author","Giagounidis, Aristoteles"],["dc.contributor.author","Loken, Michael"],["dc.contributor.author","Orfao, Alberto"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Ogata, Kiyoyuki"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Béné, Marie C."],["dc.contributor.author","Hoermann, Gregor"],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Sotlar, Karl"],["dc.contributor.author","Bettelheim, Peter"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Horny, Hans-Peter"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Greenberg, Peter"],["dc.contributor.author","Bennett, John M."],["dc.date.accessioned","2019-12-17T12:21:04Z"],["dc.date.accessioned","2021-10-27T13:21:59Z"],["dc.date.available","2019-12-17T12:21:04Z"],["dc.date.available","2021-10-27T13:21:59Z"],["dc.date.issued","2017"],["dc.description.abstract","Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between ´normal´, pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice."],["dc.identifier.doi","10.18632/oncotarget.19008"],["dc.identifier.eissn","1949-2553"],["dc.identifier.pmid","29088721"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92060"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1949-2553"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.subject.ddc","610"],["dc.title","Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Mueller, Thomas"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Gattermann, Norbert"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Steidl, Christian"],["dc.date.accessioned","2018-11-07T08:57:36Z"],["dc.date.available","2018-11-07T08:57:36Z"],["dc.date.issued","2006"],["dc.format.extent","79A"],["dc.identifier.isi","000242440000253"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23435"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Evidence for an underestimation of the prognostic impact of poor cytogenetics within the IPSS."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2704"],["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","2706"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:08:11Z"],["dc.date.available","2018-11-07T09:08:11Z"],["dc.date.issued","2012"],["dc.identifier.doi","10.1200/JCO.2012.43.8267"],["dc.identifier.isi","000306556900027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25970"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","0732-183X"],["dc.title","Cytogenetic Risk Stratification in Myelodysplastic Syndromes: Are We There Yet? Reply"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]